New publication

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting.

Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M.

Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152. [Epub ahead of print]

Kommentar schreiben

Kommentare: 0

Fr

16

Apr

2021

Vorbereitungen R├╗zje Wyn 2021

Sa

24

Okt

2020

Kroatien 2020

Sa

23

Mai

2020

Arc-en-ciel

Thanks to Saskia and Patrick for these recordings

mehr lesen